News and Events
Stay informed about RECOVER’s Long COVID research by reading the latest news and participating in upcoming events.
Featured News Item
A year of discovery: Looking back at 2025 and ahead to 2026
In 2025, RECOVER’s progress included closing the first phase of its adult observational study and publishing its first clinical trial results. This year, the initiative continues its studies and sharing research findings.
Feature
31 Results
31 Results
R3 Seminar Recap: Understanding metformin use and Long COVID and ME/CFS following COVID-19 infection: Insights from two studies
A recent RECOVER Research Review (R3) Seminar held May 13 spotlighted research presented by Carolyn Bramante, MD, MPH (University of Minnesota) and Steve Johnson, PhD (University of Minnesota) exploring how metformin, a widely prescribed medication primarily used to manage type 2 diabetes, may help reduce the risk of Long COVID. The seminar also featured a presentation from Suzanne Vernon, PhD (Bateman Horne Center) on research examining the risk of developing myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) following a COVID-19 infection.
R3 Seminar Recap
RECOVER study highlights variations in Long COVID symptoms among children of different backgrounds
RECOVER researchers studied health records to understand how racial and ethnic backgrounds may impact pediatric Long COVID symptoms. These findings could support early detection and management of Long COVID symptoms for all children.
Feature
R3 Seminar Recap: Effectiveness of Paxlovid in Protecting Against Long COVID: EHR Insights
During the April 8th RECOVER Research Review (R3) Seminar, RECOVER researchers Hannah Mandel, MS, Fei Wang, PhD, Sandy Preiss, MS, and Abhishek Bhatia, MS presented findings from two different studies of electronic health records (EHRs). Rainu Kaushal, MD (Cornell University), Dr. Wang’s co-author, joined the presenters for the panel discussion and audience Q&A. Both studies examined whether taking the antiviral drug Paxlovid during a COVID-19 infection could help prevent Long COVID. Although Paxlovid is known to reduce the risk of severe COVID-19, there has been limited research into how Paxlovid might impact a person’s risk of developing Long COVID. The studies presented are two of the largest to date that have explored the role of Paxlovid in Long COVID prevention.
R3 Seminar Recap
RECOVER Representatives inform Long COVID research through authorship
Over the last two years, RECOVER Patient, Caregiver, and Community Representatives have helped plan and write more than 100 publications about RECOVER’s Long COVID research and its findings.
Feature
Reviewing RECOVER’s impact in 2024
In 2024, RECOVER continued to advance scientific understanding of Long COVID through observational studies, clinical trials, and community engagement.
Feature
NIH directors highlight RECOVER’s progress and impact
Editorial by NIH leaders shares how RECOVER has worked and will continue working to ease the suffering of those living with Long COVID.
Announcement
NIH adds funds to Long COVID research, advances work on new clinical trials
The $662 million in funds received in 2024 will ensure that researchers can continue making progress toward understanding, diagnosing, preventing, and treating Long COVID through 2029.
News Release
RECOVER Research Update: November 2024
Recent findings from across RECOVER’s five research areas could improve our ability to identify people with Long COVID, understand the underlying causes of their symptoms, and provide them with care and treatment.
Research Update